These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 9888470

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.
    Raitanen M, Rantanen V, Kulmala J, Helenius H, Grénman R, Grénman S.
    Int J Cancer; 2002 Jul 10; 100(2):238-43. PubMed ID: 12115575
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Smith JA, Ngo H, Martin MC, Wolf JK.
    Gynecol Oncol; 2005 Jul 10; 98(1):141-5. PubMed ID: 15963813
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.
    Erjala K, Raitanen M, Kulmala J, Grénman R.
    J Cancer Res Clin Oncol; 2007 Mar 10; 133(3):169-76. PubMed ID: 17021904
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay.
    Engblom P, Rantanen V, Kulmala J, Grènman S.
    Anticancer Res; 1996 Mar 10; 16(4A):1743-7. PubMed ID: 8712694
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun 10; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).
    Tsai CM, Gazdar AF, Venzon DJ, Steinberg SM, Dedrick RL, Mulshine JL, Kramer BS.
    Cancer Res; 1989 May 01; 49(9):2390-7. PubMed ID: 2706626
    [Abstract] [Full Text] [Related]

  • 17. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.
    Braakhuis BJ, Hill BT, Dietel M, Kelland LR, Aapro MS, Zoli W, Lelieveld P.
    Anticancer Res; 1994 May 01; 14(1A):205-8. PubMed ID: 7909419
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.
    Marth C, Zeimet AG, Widschwendter M, Ludescher C, Kaern J, Tropé C, Gastl G, Daxenbichler G, Dapunt O.
    Cancer Res; 1997 Sep 01; 57(17):3818-22. PubMed ID: 9288793
    [Abstract] [Full Text] [Related]

  • 19. In vitro responses of ovarian cancers to platinums and taxanes.
    Kornblith P, Wells A, Gabrin MJ, Piwowar J, Chattopadhyay A, George LD, Ochs RL, Burholt D.
    Anticancer Res; 2003 Sep 01; 23(1B):543-8. PubMed ID: 12680143
    [Abstract] [Full Text] [Related]

  • 20. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
    Viale M, Pastrone I, Pellecchia C, Vannozzi MO, Cafaggi S, Esposito M.
    Anticancer Drugs; 1998 Jun 01; 9(5):457-63. PubMed ID: 9660544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.